Drugs in Dev. Urology
Phase III
Switzerland 
Lead Product(s) : Vibegron
Therapeutic Area : Urology
Study Phase : Phase III
Sponsor : Sumitovant Biopharma
Deal Size : $584.0 million
Deal Type : Merger
Details : The merger may enable Urovant's team to fully concentrate on the important task of preparing for its potential commercial launch of vibegron, the first new branded prescription drug for the treatment of OAB in nearly a decade.
Product Name : Gemtesa
Product Type : Other Small Molecule
Upfront Cash : Undisclosed
December 11, 2020
Lead Product(s) : Vibegron
Therapeutic Area : Urology
Highest Development Status : Phase III
Sponsor : Sumitovant Biopharma
Deal Size : $584.0 million
Deal Type : Merger
Details : Results from the 40-week EMPOWUR extension to the 12-week EMPOWUR trial shows that 75 mg of vibegron was well tolerated over the total exposure of 52 weeks with numerically greater improvements from baseline, compared to tolterodine across QoL and respon...
Product Name : Gemtesa
Product Type : Other Small Molecule
Upfront Cash : Inapplicable
November 19, 2020
Lead Product(s) : Vibegron
Therapeutic Area : Urology
Study Phase : Phase III
Sponsor : Sumitovant Biopharma
Deal Size : Undisclosed
Deal Type : Collaboration
Sumitovant Biopharma Announces Urovant Sciences Collaboration with Sunovion Pharmaceuticals
Details : The exclusive three-year distribution agreement with aims to support the commercialization of vibegron, an investigational agent for the treatment of overactive bladder.
Product Name : Gemtesa
Product Type : Other Small Molecule
Upfront Cash : Undisclosed
June 19, 2020
Lead Product(s) : Vibegron
Therapeutic Area : Urology
Highest Development Status : Phase III
Sponsor : Sumitovant Biopharma
Deal Size : Undisclosed
Deal Type : Collaboration
Details : 52-week post hoc analysis shows Vibegron patients had statistically significant, sustained reduction in UUI and total incontinence episodes compared to active control.
Product Name : Gemtesa
Product Type : Other Small Molecule
Upfront Cash : Inapplicable
May 14, 2020
Urovant Sciences Announces Publication of Phase 3 EMPOWUR Trial Results
Details : The double-blind, placebo-controlled 12-week trial, in patients with OAB, studied vibegron 75 mg once-daily compared to placebo and included an active control.
Product Name : Gemtesa
Product Type : Other Small Molecule
Upfront Cash : Inapplicable
February 03, 2020
Details : Undisclosed
Product Name : Undisclosed
Product Type : Other Small Molecule
Upfront Cash : Inapplicable
September 25, 2019
Details : Undisclosed
Product Name : Undisclosed
Product Type : Other Small Molecule
Upfront Cash : Inapplicable
April 03, 2019
Details : Undisclosed
Product Name : Undisclosed
Product Type : Other Small Molecule
Upfront Cash : Inapplicable
July 11, 2018
Details : Undisclosed
Product Name : Undisclosed
Product Type : Other Small Molecule
Upfront Cash : Inapplicable
April 10, 2018
Lead Product(s) : Desmopressin Acetate
Therapeutic Area : Urology
Study Phase : Phase III
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Details : Undisclosed
Product Name : Undisclosed
Product Type : Other Small Molecule
Upfront Cash : Inapplicable
February 13, 2017
Lead Product(s) : Desmopressin Acetate
Therapeutic Area : Urology
Highest Development Status : Phase III
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Reset All
